Through the selective modulation of the CD28 co-stimulatory pathway or direct binding to CD80 and CD86, abatacept may target additional cell types implicated in the pathogenesis of RA, contributing to the observed clinical effects. This evidence concerns the gene CD86 and rheumatoid arthritis.